<DOC>
	<DOC>NCT00415961</DOC>
	<brief_summary>This trial aims to demonstrate the non-inferiority of the CI-CMS-005 Coronary Stent System to the study device as well as to the TAXUS™ Express2™ Drug-Eluting Coronary Stent System in in-segment late lumen loss at 9 months after treatment of a single de novo lesion per vessel.</brief_summary>
	<brief_title>Multi-Center Clinical Trial: Evaluation of Effectiveness and Safety</brief_title>
	<detailed_description>This is a complementary, multi-center, open-label, single-arm trial investigating angiographic and clinical patient outcomes in Japan. Historical data from the 2-arm randomized COSTAR II trial will be used for comparison.</detailed_description>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>General Inclusion Criteria Eligible for percutaneous coronary intervention (PCI) Documented stable or unstable angina pectoris (Class I, II, III or IV), documented ischemia, or documented silent ischemia Documented LVEF ≥25% within the last 6 weeks. Eligible for coronary artery bypass graft surgery (CABG) General Known sensitivity to paclitaxel or polymeric matrices. Planned treatment with any other PCI device in the target vessel(s). MI within 72 hours prior to the index procedure Patient is in cardiogenic shock Cerebrovascular Accident (CVA) within the past 6 months Acute or chronic renal dysfunction (creatinine &gt;2.0 mg/dl or &gt;150 µmol/L) Contraindication to ASA or to ticlopidine Thrombocytopenia Active GI bleeding within past three months Known allergy to cobalt chromium Any prior true anaphylactic reaction to contrast agents</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>95 Years</maximum_age>
	<verification_date>January 2009</verification_date>
	<keyword>Percutaneous Coronary Intervention (PCI)</keyword>
	<keyword>Drug-eluting stent (DES)</keyword>
</DOC>